Autoantibodies to BACE1 promote Aβ accumulation and neurodegeneration in Alzheimer's disease.
Amyloid Precursor Protein Secretases
/ metabolism
Alzheimer Disease
/ immunology
Aspartic Acid Endopeptidases
/ metabolism
Humans
Animals
Autoantibodies
/ immunology
Female
Male
Amyloid beta-Peptides
/ metabolism
Aged
Mice
Mice, Transgenic
Aged, 80 and over
Cohort Studies
Brain
/ pathology
Amyloid beta-Protein Precursor
/ metabolism
Middle Aged
Alzheimer’s disease
Autoantibodies
Aβ amyloid
BACE1
Cognitive impairment
Journal
Acta neuropathologica
ISSN: 1432-0533
Titre abrégé: Acta Neuropathol
Pays: Germany
ID NLM: 0412041
Informations de publication
Date de publication:
24 Oct 2024
24 Oct 2024
Historique:
received:
25
03
2024
accepted:
07
10
2024
revised:
14
09
2024
medline:
25
10
2024
pubmed:
25
10
2024
entrez:
24
10
2024
Statut:
epublish
Résumé
The profile of autoantibodies is dysregulated in patients with Alzheimer's disease (AD). Autoantibodies to beta-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1) are present in human blood. This study aims to investigate the clinical relevance and pathophysiological roles of autoantibodies to BACE1 in AD. Clinical investigations were conducted in two independent cohorts, the Chongqing cohort, and the Australian Imaging, Biomarkers, and Lifestyle (AIBL) cohort. The Chongqing cohort included 55 AD patients, 28 patients with non-AD dementia, and 70 cognitively normal subjects (CN). The AIBL cohort included 162 Aβ-PET
Identifiants
pubmed: 39448400
doi: 10.1007/s00401-024-02814-x
pii: 10.1007/s00401-024-02814-x
doi:
Substances chimiques
Amyloid Precursor Protein Secretases
EC 3.4.-
Aspartic Acid Endopeptidases
EC 3.4.23.-
Autoantibodies
0
BACE1 protein, human
EC 3.4.23.46
Amyloid beta-Peptides
0
Amyloid beta-Protein Precursor
0
Bace1 protein, mouse
EC 3.4.23.46
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
57Subventions
Organisme : National Natural Science Foundation of China
ID : 82222023
Organisme : National Natural Science Foundation of China
ID : 81971024
Organisme : Innovative Research Group Project of the National Natural Science Foundation of China
ID : 81930028
Organisme : National-Level Reserve Talent Program of the Chongqing Health Commission
ID : HBRC202402
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Alexopoulos P, Thierjung N, Grimmer T, Ortner M, Economou P, Assimakopoulos K et al (2018) Cerebrospinal fluid BACE1 activity and sAβPPβ as biomarker candidates of Alzheimer’s disease. Dement Geriatr Cogn Disord 45:152–161. https://doi.org/10.1159/000488481
doi: 10.1159/000488481
pubmed: 29788013
Aprahamian T, Bonegio RG, Richez C, Yasuda K, Chiang LK, Sato K et al (2009) The peroxisome proliferator-activated receptor gamma agonist rosiglitazone ameliorates murine lupus by induction of adiponectin. J Immunol 182:340–346. https://doi.org/10.4049/jimmunol.182.1.340
doi: 10.4049/jimmunol.182.1.340
pubmed: 19109165
Atwal JK, Chen Y, Chiu C, Mortensen DL, Meilandt WJ, Liu Y et al (2011) A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo. Sci Transl Med 3:84ra43. https://doi.org/10.1126/scitranslmed.3002254
doi: 10.1126/scitranslmed.3002254
pubmed: 21613622
Bettcher BM, Tansey MG, Dorothee G, Heneka MT (2021) Peripheral and central immune system crosstalk in Alzheimer disease - a research prospectus. Nat Rev Neurol 17:689–701. https://doi.org/10.1038/s41582-021-00549-x
doi: 10.1038/s41582-021-00549-x
pubmed: 34522039
pmcid: 8439173
Bristol JA, Brand J, Ohashi M, Eichelberg MR, Casco A, Nelson SE et al (2022) Reduced IRF4 expression promotes lytic phenotype in Type 2 EBV-infected B cells. PLoS Pathog 18:e1010453. https://doi.org/10.1371/journal.ppat.1010453
doi: 10.1371/journal.ppat.1010453
pubmed: 35472072
pmcid: 9041801
Butterfield DA, Halliwell B (2019) Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat Rev Neurosci 20:148–160. https://doi.org/10.1038/s41583-019-0132-6
doi: 10.1038/s41583-019-0132-6
pubmed: 30737462
pmcid: 9382875
Calabrese EJ (2001) Amyloid beta-peptide: biphasic dose responses. Crit Rev Toxicol 31:605–606. https://doi.org/10.1080/20014091111857
doi: 10.1080/20014091111857
pubmed: 11504184
DeMarshall CA, Nagele EP, Sarkar A, Acharya NK, Godsey G, Goldwaser EL et al (2016) Detection of Alzheimer’s disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers. Alzheimers Dement (Amst) 3:51–62. https://doi.org/10.1016/j.dadm.2016.03.002
doi: 10.1016/j.dadm.2016.03.002
pubmed: 27239548
Deng J, Hou H, Giunta B, Mori T, Wang Y-J, Fernandez F et al (2012) Autoreactive-Aβ antibodies promote APP β-secretase processing. J Neurochem 120:732–740. https://doi.org/10.1111/j.1471-4159.2011.07629.x
doi: 10.1111/j.1471-4159.2011.07629.x
pubmed: 22188568
pmcid: 3278497
Diamond B, Honig G, Mader S, Brimberg L, Volpe BT (2013) Brain-reactive antibodies and disease. Annu Rev Immunol 31:345–385. https://doi.org/10.1146/annurev-immunol-020711-075041
doi: 10.1146/annurev-immunol-020711-075041
pubmed: 23516983
pmcid: 4401150
Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, Forster S et al (2013) Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer’s disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 12:233–243. https://doi.org/10.1016/S1474-4422(13)70014-0
doi: 10.1016/S1474-4422(13)70014-0
pubmed: 23375965
pmcid: 4986921
Dujardin S, Commins C, Lathuiliere A, Beerepoot P, Fernandes AR, Kamath TV et al (2020) Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease. Nat Med 26:1256–1263. https://doi.org/10.1038/s41591-020-0938-9
doi: 10.1038/s41591-020-0938-9
pubmed: 32572268
pmcid: 7603860
Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P et al (2009) The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer’s disease. Int Psychogeriatr 21:672–687. https://doi.org/10.1017/S1041610209009405
doi: 10.1017/S1041610209009405
pubmed: 19470201
Fillit H, Hess G, Hill J, Bonnet P, Toso C (2009) IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology 73:180–185. https://doi.org/10.1212/WNL.0b013e3181ae7aaf
doi: 10.1212/WNL.0b013e3181ae7aaf
pubmed: 19620605
Frisoni GB, Altomare D, Thal DR, Ribaldi F, van der Kant R, Ossenkoppele R et al (2022) The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nat Rev Neurosci 23:53–66. https://doi.org/10.1038/s41583-021-00533-w
doi: 10.1038/s41583-021-00533-w
pubmed: 34815562
Fuller JP, Stavenhagen JB, Teeling JL (2014) New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer’s Disease. Front Neurosci 8:235. https://doi.org/10.3389/fnins.2014.00235
doi: 10.3389/fnins.2014.00235
pubmed: 25191216
pmcid: 4139653
Hansen N, Malchow B, Zerr I, Stocker W, Wiltfang J, Timaus C (2021) Neural cell-surface and intracellular autoantibodies in patients with cognitive impairment from a memory clinic cohort. J Neural Transm (Vienna) 128:357–369. https://doi.org/10.1007/s00702-021-02316-0
doi: 10.1007/s00702-021-02316-0
pubmed: 33677623
Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G (2002) Increased expression of the amyloid precursor beta-secretase in Alzheimer’s disease. Ann Neurol 51:783–786. https://doi.org/10.1002/ana.10208
doi: 10.1002/ana.10208
pubmed: 12112088
Jian JM, Fan DY, Tian DY, Cheng Y, Sun PY, Tan CR et al (2022) Naturally-occurring antibodies against Bim are decreased in Alzheimer’s disease and attenuate AD-type pathology in a mouse model. Neurosci Bull. https://doi.org/10.1007/s12264-022-00869-y
doi: 10.1007/s12264-022-00869-y
pubmed: 35974288
pmcid: 9905456
Jiao SS, Bu XL, Liu YH, Zhu C, Wang QH, Shen LL et al (2016) Sex dimorphism profile of Alzheimer’s disease-type pathologies in an app/ps1 mouse model. Neurotox Res 29:256–266. https://doi.org/10.1007/s12640-015-9589-x
doi: 10.1007/s12640-015-9589-x
pubmed: 26707129
Jiao SS, Yao XQ, Liu YH, Wang QH, Zeng F, Lu JJ et al (2015) Edaravone alleviates Alzheimer’s disease-type pathologies and cognitive deficits. Proc Natl Acad Sci U S A 112:5225–5230. https://doi.org/10.1073/pnas.1422998112
doi: 10.1073/pnas.1422998112
pubmed: 25847999
pmcid: 4413288
Jin WS, Shen LL, Bu XL, Zhang WW, Chen SH, Huang ZL et al (2017) Peritoneal dialysis reduces amyloid-beta plasma levels in humans and attenuates Alzheimer-associated phenotypes in an APP/PS1 mouse model. Acta Neuropathol 134:207–220. https://doi.org/10.1007/s00401-017-1721-y
doi: 10.1007/s00401-017-1721-y
pubmed: 28477083
Kocurova G, Ricny J, Ovsepian SV (2022) Autoantibodies targeting neuronal proteins as biomarkers for neurodegenerative diseases. Theranostics 12:3045–3056. https://doi.org/10.7150/thno.72126
doi: 10.7150/thno.72126
pubmed: 35547759
pmcid: 9065204
Li J, Wang YJ, Zhang M, Xu ZQ, Gao CY, Fang CQ et al (2011) Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology 76:1485–1491. https://doi.org/10.1212/WNL.0b013e318217e7a4
doi: 10.1212/WNL.0b013e318217e7a4
pubmed: 21490316
Liu L, Martin R, Kohler G, Chan C (2013) Palmitate induces transcriptional regulation of BACE1 and presenilin by STAT3 in neurons mediated by astrocytes. Exp Neurol 248:482–490. https://doi.org/10.1016/j.expneurol.2013.08.004
doi: 10.1016/j.expneurol.2013.08.004
pubmed: 23968646
pmcid: 3787872
Liu YH, Bu XL, Liang CR, Wang YR, Zhang T, Jiao SS et al (2015) An N-terminal antibody promotes the transformation of amyloid fibrils into oligomers and enhances the neurotoxicity of amyloid-beta: the dust-raising effect. J Neuroinflammation 12:153. https://doi.org/10.1186/s12974-015-0379-4
doi: 10.1186/s12974-015-0379-4
pubmed: 26311039
pmcid: 4551765
Liu YH, Wang J, Li QX, Fowler CJ, Zeng F, Deng J et al (2021) Association of naturally occurring antibodies to β-amyloid with cognitive decline and cerebral amyloidosis in Alzheimer’s disease. Sci Adv. https://doi.org/10.1126/sciadv.abb0457
doi: 10.1126/sciadv.abb0457
pubmed: 34936449
pmcid: 11426200
Liu YH, Zeng F, Wang YR, Zhou HD, Giunta B, Tan J et al (2013) Immunity and Alzheimer’s disease: immunological perspectives on the development of novel therapies. Drug Discov Today 18:1212–1220. https://doi.org/10.1016/j.drudis.2013.07.020
doi: 10.1016/j.drudis.2013.07.020
pubmed: 23954180
McDade E, Voytyuk I, Aisen P, Bateman RJ, Carrillo MC, De Strooper B et al (2021) The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. Nat Rev Neurol 17:703–714. https://doi.org/10.1038/s41582-021-00545-1
doi: 10.1038/s41582-021-00545-1
pubmed: 34548654
Minett T, Classey J, Matthews FE, Fahrenhold M, Taga M, Brayne C et al (2016) Microglial immunophenotype in dementia with Alzheimer’s pathology. J Neuroinflammation 13:135. https://doi.org/10.1186/s12974-016-0601-z
doi: 10.1186/s12974-016-0601-z
pubmed: 27256292
pmcid: 4890505
Mormino EC, Papp KV, Rentz DM, Donohue MC, Amariglio R, Quiroz YT et al (2017) Early and late change on the preclinical Alzheimer’s cognitive composite in clinically normal older individuals with elevated amyloid beta. Alzheimers Dement 13:1004–1012. https://doi.org/10.1016/j.jalz.2017.01.018
doi: 10.1016/j.jalz.2017.01.018
pubmed: 28253478
Nagele RG, Clifford PM, Siu G, Levin EC, Acharya NK, Han M et al (2011) Brain-reactive autoantibodies prevalent in human sera increase intraneuronal amyloid-β(1–42) deposition. J Alzheimers Dis 25:605–622. https://doi.org/10.3233/JAD-2011-110098
doi: 10.3233/JAD-2011-110098
pubmed: 21483091
Nicsanu R, Cervellati C, Benussi L, Squitti R, Zanardini R, Rosta V et al (2022) Increased serum beta-secretase 1 activity is an early marker of Alzheimer’s disease. J Alzheimers Dis 87:433–441. https://doi.org/10.3233/JAD-215542
doi: 10.3233/JAD-215542
pubmed: 35275540
pmcid: 9198762
Paquet C, Amin J, Mouton-Liger F, Nasser M, Love S, Gray F et al (2015) Effect of active Abeta immunotherapy on neurons in human Alzheimer’s disease. J Pathol 235:721–730. https://doi.org/10.1002/path.4491
doi: 10.1002/path.4491
pubmed: 25430817
Qiu H, Liu X (2022) Echinacoside improves cognitive impairment by inhibiting abeta deposition through the pi3k/akt/nrf2/ppargamma signaling pathways in app/ps1 mice. Mol Neurobiol 59:4987–4999. https://doi.org/10.1007/s12035-022-02885-5
doi: 10.1007/s12035-022-02885-5
pubmed: 35665898
pmcid: 9363339
Relkin NR, Thomas RG, Rissman RA, Brewer JB, Rafii MS, van Dyck CH et al (2017) A phase 3 trial of IV immunoglobulin for Alzheimer disease. Neurology 88:1768–1775. https://doi.org/10.1212/WNL.0000000000003904
doi: 10.1212/WNL.0000000000003904
pubmed: 28381506
pmcid: 5409846
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W et al (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43:e47. https://doi.org/10.1093/nar/gkv007
doi: 10.1093/nar/gkv007
pubmed: 25605792
pmcid: 4402510
Robinson MD, Oshlack A (2010) A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol 11:R25. https://doi.org/10.1186/gb-2010-11-3-r25
doi: 10.1186/gb-2010-11-3-r25
pubmed: 20196867
pmcid: 2864565
San Segundo-Acosta P, Montero-Calle A, Jernbom-Falk A, Alonso-Navarro M, Pin E, Andersson E et al (2021) Multiomics profiling of Alzheimer’s disease serum for the identification of autoantibody biomarkers. J Proteome Res 20:5115–5130. https://doi.org/10.1021/acs.jproteome.1c00630
doi: 10.1021/acs.jproteome.1c00630
pubmed: 34628858
Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F et al (2003) Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 23:9796–9804. https://doi.org/10.1523/JNEUROSCI.23-30-09796.2003
doi: 10.1523/JNEUROSCI.23-30-09796.2003
pubmed: 14586007
pmcid: 6740896
Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P et al (2006) Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci USA 103:443–448. https://doi.org/10.1073/pnas.0503839103
doi: 10.1073/pnas.0503839103
pubmed: 16407166
pmcid: 1326151
Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE et al (2021) Alzheimer’s disease. Lancet 397:1577–1590. https://doi.org/10.1016/s0140-6736(20)32205-4
doi: 10.1016/s0140-6736(20)32205-4
pubmed: 33667416
pmcid: 8354300
Sgrignani J, Olsson S, Ekonomiuk D, Genini D, Krause R, Catapano CV et al (2015) Molecular determinants for unphosphorylated STAT3 dimerization determined by integrative modeling. Biochemistry 54:5489–5501. https://doi.org/10.1021/bi501529x
doi: 10.1021/bi501529x
pubmed: 26283080
Shen Y, Wang H, Sun Q, Yao H, Keegan AP, Mullan M et al (2018) Increased plasma beta-secretase 1 may predict conversion to Aalzheimer’s disease dementia in individuals with mild cognitive impairment. Biol Psychiatry 83:447–455. https://doi.org/10.1016/j.biopsych.2017.02.007
doi: 10.1016/j.biopsych.2017.02.007
pubmed: 28359566
Sigdel TK, Shoemaker LD, Chen R, Li L, Butte AJ, Sarwal MM et al (2013) Immune response profiling identifies autoantibodies specific to Moyamoya patients. Orphanet J Rare Dis 8:45. https://doi.org/10.1186/1750-1172-8-45
doi: 10.1186/1750-1172-8-45
pubmed: 23518061
pmcid: 3648437
Wang BZ, Zailan FZ, Wong BYX, Ng KP, Kandiah N (2020) Identification of novel candidate autoantibodies in Alzheimer’s disease. Eur J Neurol 27:2292–2296. https://doi.org/10.1111/ene.14290
doi: 10.1111/ene.14290
pubmed: 32356904
Wang YR, Wang MT, Zeng XQ, Liu YH, Wang YJ (2022) Associations of naturally occurring antibodies to presenilin-1 with brain amyloid-beta load and cognitive impairment in Alzheimer’s disease. J Alzheimers Dis 90:1493–1500. https://doi.org/10.3233/JAD-220775
doi: 10.3233/JAD-220775
pubmed: 36278353
Xiang Y, Bu XL, Liu YH, Zhu C, Shen LL, Jiao SS et al (2015) Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer’s disease. Acta Neuropathol 130:487–499. https://doi.org/10.1007/s00401-015-1477-1
doi: 10.1007/s00401-015-1477-1
pubmed: 26363791
pmcid: 4575389
Xiang Y, Meng S, Wang J, Li S, Liu J, Li H et al (2014) Two novel DNA motifs are essential for BACE1 gene transcription. Sci Rep 4:6864. https://doi.org/10.1038/srep06864
doi: 10.1038/srep06864
pubmed: 25359283
pmcid: 4215305
Zhang M, Zhong X, Shi H, Vanmechelen E, De Vos A, Liu S et al (2020) BACE1 and other Alzheimer’s-related biomarkers in cerebrospinal fluid and plasma distinguish Alzheimer’s disease patients from cognitively-impaired neurosyphilis patients. J Alzheimers Dis 77:313–322. https://doi.org/10.3233/JAD-200362
doi: 10.3233/JAD-200362
pubmed: 32804135
Zhou H, Deng J, Li J, Wang Y, Zhang M, He H (2003) Study of the relationship between cigarette smoking, alcohol drinking and cognitive impairment among elderly people in China. Age Ageing 32:205–210
doi: 10.1093/ageing/32.2.205
pubmed: 12615566
Zhu F, He P, Jiang W, Afridi SK, Xu H, Alahmad M et al (2024) Astrocyte-secreted C3 signaling impairs neuronal development and cognition in autoimmune diseases. Prog Neurobiol 240:102654. https://doi.org/10.1016/j.pneurobio.2024.102654
doi: 10.1016/j.pneurobio.2024.102654
pubmed: 38945516